TherapeuticsMD (TXMD) Misses Q2 EPS by 17c

TherapeuticsMD (NASDAQ: TXMD) reported Q2 EPS of ($0.24), $0.17 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Is the global equity rally broadening? UBS weighs in
• CoStar Group acquires Zonda for $800M, adding new home data
• Zurn Water Solutions (ZWS) Reiterated at Buy by Stifel on New Product Development Momentum